AstraZeneca To Settle Toprol-XL Antitrust Action

Law360, New York (May 31, 2012, 3:41 PM EDT) -- AstraZeneca Pharmaceuticals LP reached an agreement Wednesday to resolve claims brought in Delaware by a putative class of indirect purchasers of Toprol-XL who allege the pharmaceutical giant used sham patent litigation to delay generic competition for the hypertension drug.

Chief U.S. District Judge Gregory M. Sleet signed off on an order staying the case following a joint notice that informed the court the parties had reached an "agreement in principle" to settle all claims. The order suspended all deadlines in the case and removed from the...
To view the full article, register now.